@article{2fd6a0971bb34e99aa6e1ff5802cba59,
title = "New options for the management of chronic hyperkalemia",
abstract = "Hyperkalemia is a frequently detected electrolyte abnormality that can cause life-threatening complications. Hyperkalemia is most often the result of intrinsic (decreased glomerular filtration rate; selective reduction in distal tubule secretory function; impaired mineralocorticoid activity; and metabolic disturbances, such as acidemia and hyperglycemia) and extrinsic factors (e.g., drugs, such as renin-angiotensin-aldosterone system inhibitors, and potassium intake). The frequent use of renin-angiotensin-aldosterone system inhibitors in patients who are already susceptible to hyperkalemia (e.g., patients with chronic kidney disease, diabetes mellitus, or congestive heart failure) contributes to the high incidence of hyperkalemia. There is a need to understand the causes of hyperkalemia and to be aware of strategies addressing the disorder in a way that provides the most optimal outcome for affected patients. The recent development of 2 new oral potassium-binding agents has led to the emergence of a new paradigm in the treatment of hyperkalemia.",
keywords = "chronic kidney disease, hyperkalemia, potassium, treatment",
author = "Linda Fried and Kovesdy, {Csaba P.} and Palmer, {Biff F.}",
note = "Funding Information: Publication of this article was supported by AstraZeneca. This supplement summarizes the two continuing medical education meetings held during the International Society of Nephrology/World Congress of Nephrology conference. The two educational meetings were supported by an educational grant from FibroGen and AstraZeneca. FibroGen and AstraZeneca had no involvement in the development of the two continuing medical education meetings or this supplement. The Med Ed Group, Inc, the meeting organizers, provided editorial support for this supplement. SynAptiv accredited the two continuing medical education meetings and has reviewed this supplement. Funding Information: Publication of this article was supported by AstraZeneca. LF has received speaking and consultant honoraria from Bayer and Sanofi, and research support from Abbvie. CPK has received speaking and consultant honoraria and advisory fees from Abbott, Abbvie, Amgen, AstraZeneca, Bayer, Fresenius Medical Care, Genzyme, Keryx, and Sanofi-Aventis; research support from Shire; travel support from Abbott, Abbvie, Amgen, Bayer, Keryx, Fresenius Medical Care, and Sanofi-Aventis; and NIH-NIDDK funding. BFP declared no completing interests. Publisher Copyright: {\textcopyright} 2017",
year = "2017",
month = dec,
doi = "10.1016/j.kisu.2017.09.001",
language = "English (US)",
volume = "7",
pages = "164--170",
journal = "Kidney International Supplements",
issn = "2157-1724",
publisher = "Nature Publishing Group",
number = "3",
}